



Senti Biosciences Announces Dr. Gary Lee as Chief Scientific Officer

Synthetic biology company taps veteran biotech executive to drive next-generation cell and gene therapy programs into the clinic

South San Francisco, October 23, 2018 -- Senti Biosciences, the leading synthetic biology company developing next-generation adaptive therapies, today announced that Gary Lee, Ph.D., has joined the company as Chief Scientific Officer. As CSO, Dr. Lee will lead the expansion of Senti's synthetic biology technology platform and the advancement of internal cell therapy programs to the clinic in multiple oncology indications.

Senti Biosciences develops synthetic gene circuits for adaptive cell and gene therapies that respond dynamically to different disease states. Senti's technology platform enables living cellular therapies that can be controlled once administered, targeted to disease sites, and customized for multifactorial responses based on the disease state and desired therapeutic outcome. Senti is currently advancing wholly owned internal cell therapy programs toward the clinic for the treatment of solid and liquid tumors, and is investigating partnerships with companies to apply its platform beyond oncology.

"We are excited to have Gary join us as Chief Scientific Officer. Gary has spent his entire career building cell and gene therapies from the ground up, and brings a wealth of experience to the Senti team, both as a scientist and executive," said Tim Lu, CEO of Senti Biosciences. "Gary's technical expertise in engineering T cells and translating cell and gene therapies into the clinic will be critical as we continue to move toward human trials."

Dr. Lee joins Senti from Sangamo Therapeutics, where he spent the last 13 years developing T-cell and hematopoietic stem cell therapeutics, most recently as Vice President of Cell Therapy. At Sangamo, Dr. Lee led the company's programs around T-cell engineering, including CAR-T cell therapies for oncology applications (a platform recently licensed to Kite, a Gilead company) and T-cell therapies for HIV. Dr. Lee also served as the head of Sangamo's immunology/Treg therapeutic pipeline. Dr. Lee received his B.S. in Chemical Engineering from California Institute of Technology and his Ph.D. in Chemical Engineering from U.C. Berkeley.

"I'm thrilled to join the team at Senti Bio, a company at the forefront of next generation adaptive therapies," said Dr. Lee. "Senti is leading the emerging field of engineering intelligence into cells to treat complex diseases. I'm looking forward to stewarding these therapies through the clinic and into approved treatments for patients."

This announcement follows Senti's recent inclusion in Fierce Biotech's "Fierce 15," the publication's annual list of the top 15 emerging biotechnology companies, for its work on synthetic gene circuits in next generation adaptive cell therapies.

About Senti Biosciences

Senti Biosciences is a synthetic biology company pioneering adaptive cell and gene therapies to treat the most complex and challenging diseases. Using its synthetic biology technology platform, Senti designs synthetic gene circuits capable of responding dynamically to different disease states and biological settings. The company is developing an internal pipeline of therapeutic programs in oncology, and is pursuing partnerships for additional applications using its technology. Senti Biosciences is based in San Francisco and was founded in 2016 by Drs. Tim Lu, Philip Lee, Jim Collins and Wilson Wong. Senti is proud to count NEA, 8VC, Amgen Ventures, Pear Ventures, Lux Capital, Menlo Ventures, Allen & Company, Nest.Bio, Omega Funds, Goodman Capital, and LifeForce Capital among their investors.

Contact

Curt Herberts

CFO and CBO

650-906-1674

press@senti.bio